세계의 폰다파리눅스 시장 규모 : 유형별, 치료별, 투여 경로별, 지역별, 범위 및 예측

Fondaparinux Market Size And Forecast

Fondaparinux Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2024 to 2031.

Global Fondaparinux Market Drivers

The market drivers for the Fondaparinux Market can be influenced by various factors. These may include:

Rising Thromboembolic Disease Incidence:

The need for anticoagulants like fondaparinux is driven by the increased occurrence of diseases like PE and DVT, particularly in the elderly and sedentary population.

Population Ageing:

An ageing world population increases the risk of thromboembolic illnesses, which calls for efficient anticoagulant treatments. The need for Fondaparinux rises in tandem with the ageing population.

Consciousness And Assessment:

Higher diagnosis rates result from increased knowledge of thromboembolic illnesses and improved diagnostic methods, which in turn increase the use of fondaparinux as a therapeutic option.

Benefits Compared To Other Anticoagulants:

Fondaparinux is the recommended option in several clinical situations due to its unique benefits, which include a decreased risk of heparin-induced thrombocytopenia (HIT) and the absence of the requirement for routine blood testing.

Policies Of The Government And Healthcare:

The market is stimulated by government policies and healthcare programmes that support the management and prevention of thromboembolic disorders. Anticoagulant therapy reimbursement policies are also very important.

Investigation And Creation:

As anticoagulant treatments continue to be researched and developed, the market benefits from increased drug use of Fondaparinux due to its improved safety profile and efficacy.

Growing Number Of Surgical Procedures:

Prophylactic anticoagulants such as Fondaparinux are in high demand due to the increased risk of postoperative thromboembolic events resulting from the rise in surgical procedures, especially orthopaedic surgery.

Financial Elements:

The acceptance of effective anticoagulant medicines is driven by the economic burden associated with thromboembolic illnesses, including hospitalisations and long-term treatment expenditures, which aim to lower overall healthcare costs.

Extending Indications:

Market expansion is facilitated by extending the usage of fondaparinux for therapeutic indications, such as acute coronary syndrome.

Technological Progress:

Technological developments in drug administration and formulation can improve Fondaparinux's convenience and effectiveness, making it more appealing to consumers.

Global Fondaparinux Market Restraints

Several factors can act as restraints or challenges for the Fondaparinux Market. These may include:

Exorbitant Treatment Costs:

Since fondaparinux is more costly than other anticoagulants, its use and accessibility may be restricted, particularly for patients without sufficient insurance or in low-income areas.

The Accessibility Of Substitutes:

The sole market share of fondaparinux is limited by the availability of alternative anticoagulants, such as warfarin, direct oral anticoagulants (DOACs), and low molecular weight heparins (enoxaparin), which give doctors and patients more therapeutic options.

Safety Concerns And side Effects:

Fondaparinux can still result in bleeding issues even though it is less likely than heparin to produce heparin-induced thrombocytopenia (HIT). Fears of these negative consequences may prevent it from being widely used.

Regulatory Obstacles:

Because the pharmaceutical sector is so closely regulated, getting permission from authorities like the FDA and EMA may be a time-consuming and expensive procedure. Modifications to regulations may also have an effect on the market.

Restricted Indications:

Fondaparinux is mainly recommended for certain medical diseases such as PE and DVT. Market expansion may be hampered by its narrow range of indications when compared to other anticoagulants with wider therapeutic uses.

Generic Competition And Patent Expirations:

Manufacturers of generic versions of fondaparinux may become more competitive as their patents expire. Original manufacturers may see a decrease in their profit margins and prices as a result.

Consciousness And Acceptance:

Adoption of fondaparinux may be restricted if patients and healthcare professionals are unaware of its advantages over other anticoagulants. Initiatives in the areas of education and training are required to boost its usage.

Financial Elements:

The distribution of funds for pricey medicines like fondaparinux can be impacted by economic downturns and financial restrictions in healthcare systems, particularly in publicly supported healthcare systems.

Global Fondaparinux Market Segmentation Analysis

The Global Fondaparinux Market is Segmented on the basis of Type, Treatment, Route Of Administration, And Geography.

Fondaparinux Market, By Type

• Deep Vein Thrombosis (DVT):
• Fondaparinux is used to prevent blood clots from forming in the deep veins of the legs and thighs.
• Pulmonary Embolism (PE):
• Fondaparinux is also used to treat and prevent pulmonary embolisms, which are blood clots that travel to the lungs from the legs or other parts of the body.

Fondaparinux Market, By Treatment

• Medication:
• This is the primary segment, encompassing all fondaparinux drugs used for DVT and PE prevention and treatment.
• Others:
• This may include ancillary treatments used in conjunction with fondaparinux therapy.

Fondaparinux Market, By Route Of Administration

• Parenteral:
• Fondaparinux is typically administered through injection, subcutaneously (under the skin).
• Others:
• Theoretically, other routes of administration might be explored in the future, but currently, injection is the standard method.

Fondaparinux Market, By Geography

• North America:
• Market conditions and demand in the United States, Canada, and Mexico.
• Europe:
• Analysis of the Fondaparinux Market in European countries.
• Asia-Pacific:
• Focusing on countries like China, India, Japan, South Korea, and others.
• Middle East and Africa:
• Examining market dynamics in the Middle East and African regions.
• Latin America:
• Covering market trends and developments in countries across Latin America.

Key Players

• The major players in the Fondaparinux Market are:
• Pfizer
• Mylan
• Dr. Reddy's Laboratories
• Apotex
• Alchemia
• Bayer
• AGIOS
• Celgene
• Philogen S.p.A.
• Tragara/Adastra
• Aslan Pharmaceuticals
• Daiichi Sankyo
• Beigene
• Bristol-Myers Squibb
• Tesaro.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Fondaparinux Market, By Type

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)

5. Fondaparinux Market, By Treatment

• Medication
• Others

6. Fondaparinux Market, By Route Of Administration

• Parenteral
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Pfizer
• Mylan
• Dr. Reddy's Laboratories
• Apotex
• Alchemia
• Bayer
• AGIOS
• Celgene
• Philogen S.p.A.
• Tragara/Adastra

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References